Table 3 Standardised incidence ratios for GCTa in relatives by proband characteristics

From: Family history of cancer in children and adolescents with germ cell tumours: a report from the Children’s Oncology Group

Characteristic of proband

N OBSERVED

N EXPECTED

SIR (95% CI) b

Sex

Males

11

3.2

3.47 (1.42–5.52)

Females

10

2.5

3.94 (1.50–6.38)

Age at diagnosis

< 11

6

1.3

4.63 (0.93–8.34)

⩾ 11

15

5.2

2.89 (1.43–4.35)

Sex and age

Males<11

1

0.1

-

Males⩾11

10

2.5

4.05 (1.54–6.56)

Females<11

5

0.8

6.11 (0.75–11.5)

Females⩾11

5

1

5.16 (0.64-9.68)

Race

Non-Hispanic, white

19

4.5

4.26 (2.34–6.17)

Other

2

0.6

3.00 (0–7.17)

Tumour histology c

Germinoma

10

1.4

7.15 (2.72–11.59)

Teratoma

4

0.8

4.76 (0.10–9.42)

Yolk sac tumour

2

0.4

5.45 (0–13.1)

Mixed/other

4

0.4

9.14 (0.18–18.10)

Tumour location

Intracranial

12

1.5

8.07 (3.51–12.6)

Extracranial and extragonadal

2

0.5

3.78 (0–9.03)

Testis

4

0.4

11.15 (0.22–22.08)

Ovary

3

0.7

4.35 (0–9.27)

  1. Abbreviations: CI=confidence interval; IR=incidence rate per 100 000 person-years; SEER=Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov); SIR=standard incidence ratio.
  2. aGCT includes germinoma (ICCC97 9060-9065), malignant teratoma (9080-9084), embryonal carcinoma (9070-9072), yolk sac tumour (9071), choriocarcinoma (9100, 9103, 9104), and mixed GCT (9085, 9101, 9102, 9105) in all sites.
  3. bSIR using indirect standardisation: Reference population is SEER 13 population.
  4. cTumour histology was missing for one GCT proband.
Back to article page